- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04000867
Treatment for Foot Pain Caused by Diabetic Neuropathy Using Recurrent TransCutaneous Magnetic Stimulation (TCMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse will relieve foot pain from Diabetic Neuropathy (DN) if used weekly for a month The United States Food and Drug Administration (FDA) has approved a similar device for treatment of migraine headaches, but this type of device has not been studied for the treatment of DN. No significant adverse reactions or side effects have been reported from the use of magnetic stimulation for the headache treatment or for the treatment of foot pain for about 20 patients. Some patients who have migraine headaches or foot pain have excellent pain relief with the magnetic treatment even if they did not get pain relief using medications.
The initial safety and feasibility study did show it was both safe and effective but short term with most benefits wearing off after 1 week. Additionally in the initial study no placebo comparisons were made, therefore this study will consist of 20-blinded randomized patients. 10 will receive the TCMS treatment weekly and 10 will receive a sham treatment weekly both for 1 month.
Investigators believe that using the device weekly will relieve the foot pain caused by diabetic neuropathy over the course on 1 month compared with those receiving the sham treatment.
And to prove this hypothesis investigators will treat 10-blinded patients in the TCMS treatment group, they will be receiving active treatment as follows:
50 pulses to the sole of the patient's left (L) foot by placing the foot on top of the device with the heel touching the heel stop (the rear position)
Then followed by another 50 pulses to sole of the patient's L foot by either:
Moving the foot forward so the toes touch the toe stop (the forward position) or By placing the patients' foot under the pulsing deck (the under-deck position)
This procedure will then be repeated for the right (R) foot
10-blinded patients in the sham treatment group will use the same device. However, device will be switched into sham mode by the only un-blinded clinician in the study by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
Patients will receive the sham treatment the same as the TCMS treatment group, as described above and both groups will be completing a daily diary to rate and evaluate their pain and their quality of life for the month they participate in the study.
One side effect of this treatment may be some muscular jerking of the foot or the toes during the application of the magnetic pulses. This jerking will last only during the treatment and will not be painful or harmful.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Leigh Vinocur, MD
- Phone Number: 410-207-6083
- Email: leigh.vinocur@zygoodhealth.com
Study Contact Backup
- Name: Steve Kaye, MS
- Phone Number: 443-900-3097
- Email: Steve.kaye@zygoodhealth.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years of age.
- Pain duration of more than one month.
- Pain occurs daily.
- Chronic DN associated bilateral foot pain and is not explained by a central anatomic nerve compression and can clearly be correlated with that patient's history of diabetes.
- Average Pain intensity ≥ 5 in each foot for at least 3 days at the time of enrollment.
Exclusion Criteria:
- Life expectancy ≤ 6 months.
- Oral pain medication doses or active ingredient has changed significantly* in the prior 2 weeks.
- Inability to walk at least 10 steps (with or without a cane/walker) before and after having to sit in a chair.
- Another pain condition that might confound results (e.g., neuropathy from cancer chemotherapy, plantar fasciitis or arthritis of ankle and foot)
- Inability to undergo study assessments or complete questionnaires independently.
- Active psychological co-morbidities (i.e., uncontrolled schizophrenia).
- Currently using an opioid medication for the treatment of foot pain**.
- Pregnancy
- Inability to have MRI
- Metal hardware and/or fragments in feet and ankles
Implanted pacemaker or a defibrillator, unless the device is considered MRI safe
A significant change for this study is defined as a 20% increase or decrease in dosing of the patient's medication dose and/or or a change in the medication class (adding or removing other types of medicines used to treat pain).
- This exclusion is restricted to opioids, benzodiazepines and psychotropic.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: real TCMS treatment
Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.)
Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
|
The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses.
Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw.
This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
|
SHAM_COMPARATOR: Sham TCMS treatment
Patients in the sham treatment group, will use the same device.
The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator.
The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
|
The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses.
Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw.
This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Pain reduction
Time Frame: 28 day +/- 2 days
|
The primary endpoint will be defined as achieving at least reduction in average pain score from 0-10 (0 being no pain and 10 being the worst pain imaginable) )versus the sham control using pre-study average baseline for each subject as a covariate by a repeated measures analysis of pain scores through 28 days.
|
28 day +/- 2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain reduction with in the first week
Time Frame: 1 week
|
Secondary endpoints will include a responder analysis in which the percentage of subjects between the sham and test groups that achieve the minimum clinically important pain reduction of 2 or more points from the scale described above within the first week of treatment.
|
1 week
|
Improved Activities of daily living
Time Frame: 28 days +/- 2 days
|
Secondary endpoints will also include improved quality of life (ie, 1-Did the level of your pain interfere with your daily activities at home or work?
2-Did the level of your pain interfere with your social or recreational activities?
3-Did the level of your pain interfere with your sleep?) the responses as guided by the PROMIS questions ( answered as one of 5 choices Not at All A little bit Somewhat Quite a bit Very Much) included in the pre and post questionnaires and the home assessment diary booklet.
|
28 days +/- 2 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ejaz Shamim, MD, Kaiser Permanente
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCMS for DN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Peripheral Neuropathy
-
Pamlab, L.L.C.HealthCore, Inc.CompletedDiabetic Peripheral Neuropathy (DPN)United States
-
Riphah International UniversityRecruitingDiabetic Peripheral Neuropathy (DPN)Pakistan
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Wuhan Central HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China; Wuhan...RecruitingDiabetic Peripheral Neuropathy Type 2China
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
Hawler Medical UniversityUnknownDiabetic Peripheral NeuropathyIraq
-
Fengmei LianPeking Union Medical College Hospital; Huashan Hospital; Chengdu University of... and other collaboratorsUnknownDiabetic Peripheral Neuropathy Type 2China
-
Tanta UniversityActive, not recruiting
-
October 6 UniversityCompletedDiabetic Neuropathy PeripheralEgypt
Clinical Trials on Transcutaneous Magnetic Stimulation (TCMS)
-
University of Maryland, BaltimoreCompletedLower Back PainUnited States
-
University of Maryland, BaltimoreCompletedDiabetic NeuropathiesUnited States
-
VA Office of Research and DevelopmentCompletedNeuropathic PainUnited States
-
University of Sao Paulo General HospitalRecruiting
-
University of California, Los AngelesRecruiting
-
General and Teaching Hospital CeljeRecruitingCritical Illness MyopathySlovenia
-
Centre Hospitalier Universitaire de Saint EtienneLaboratoire de Physiologie de l'ExerciceRecruitingMuscle WeaknessFrance
-
Medical University of South CarolinaNational Institutes of Health (NIH)Active, not recruitingStroke | Stroke Sequelae | Motor ActivityUnited States
-
Istanbul Medipol University HospitalEnrolling by invitation
-
Bronx VA Medical CenterCompletedAmyotrophic Lateral Sclerosis (ALS) | Spinal Cord Injury (SCI)United States